A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

NCT01125748 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: Omalizumab
DRUG: Placebo
DRUG: Asthma therapies

Sponsor

Genentech, Inc.